Avicin G is a potent sphingomyelinase inhibitor and blocks oncogenic K- and H-Ras signaling.

Sci Rep

Department of Biochemistry and Molecular Biology, School of Boonshoft Medical School, Wright State University, Dayton, OH, 45435, United States.

Published: June 2020

K-Ras must interact primarily with the plasma membrane (PM) for its biological activity. Therefore, disrupting K-Ras PM interaction is a tractable approach to block oncogenic K-Ras activity. Here, we found that avicin G, a family of natural plant-derived triterpenoid saponins from Acacia victoriae, mislocalizes K-Ras from the PM and disrupts PM spatial organization of oncogenic K-Ras and H-Ras by depleting phosphatidylserine (PtdSer) and cholesterol contents, respectively,  at the inner PM leaflet. Avicin G also inhibits oncogenic K- and H-Ras signal output and the growth of K-Ras-addicted pancreatic and non-small cell lung cancer cells. We further identified that avicin G perturbs lysosomal activity, and disrupts cellular localization and activity of neutral and acid sphingomyelinases (SMases), resulting in elevated cellular sphingomyelin (SM) levels and altered SM distribution. Moreover, we show that neutral SMase inhibitors disrupt the PM localization of K-Ras and PtdSer and oncogenic K-Ras signaling. In sum, this study identifies avicin G as a new potent anti-Ras inhibitor, and suggests that neutral SMase can be a tractable target for developing anti-K-Ras therapeutics.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272413PMC
http://dx.doi.org/10.1038/s41598-020-65882-5DOI Listing

Publication Analysis

Top Keywords

oncogenic k-ras
12
avicin potent
8
oncogenic h-ras
8
neutral smase
8
k-ras
7
avicin
5
oncogenic
5
potent sphingomyelinase
4
sphingomyelinase inhibitor
4
inhibitor blocks
4

Similar Publications

SIGLEC9 (sialic acid-binding Ig-like lectin 9) is a molecule thought to have a significant influence on the immune properties of the colorectal cancer (CRC) tumor microenvironment (TME). In our study, we assessed the expression of the SIGLEC9 protein in CRC tissue and the surgical margin tissue. Using RT-PCR, we analyzed mutations in the KRAS, NRAS, BRAF, PIK3CA, and AKT genes.

View Article and Find Full Text PDF

Oncogenic mutations in the gene are detected in >90% of pancreatic cancers (PC). In genetically engineered mouse models of PC, oncogenic drives the formation of precursor lesions and their progression to invasive PC. The Yes-associated Protein (YAP) is a transcriptional coactivator required for transformation by the RAS oncogenes and the development of PC.

View Article and Find Full Text PDF

This study developed a dual-mode "on-off-on" sensor based on a bipyridine ruthenium metal-organic framework (Ru-MOF) and dual enzyme cleavage technology for the sensitive detection of the K-ras gene. The sensor combines electrogenerated chemiluminescence (ECL) and fluorescence (FL) detection modes, achieving high sensitivity and specificity in detecting the K-ras gene through catalytic hairpin assembly (CHA) and dual enzyme cleavage reactions. Experimental results showed that the detection limits for the K-ras gene were 0.

View Article and Find Full Text PDF

Targeted nanoliposomes of oncogenic protein degraders: Significant inhibition of tumor in lung-cancer bearing mice.

J Control Release

December 2024

College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA. Electronic address:

Article Synopsis
  • Around 60% of non-small cell lung cancer (NSCLC) cases express the epidermal growth factor receptor (EGFR), making it a key target for treatment, but resistance to EGFR inhibitors develops quickly and poses challenges for patients.
  • Researchers are exploring a new approach using a technique called "Proteolysis Targeting Chimeras (PROTACs)" to simultaneously degrade EGFR and Bromodomain-containing protein 4 (BRD4), which has shown promising results in cell tests with significant tumor growth inhibition.
  • A specialized formulation, T-BEPRO, utilizing nanoliposomal carriers for delivering these PROTACs, demonstrated improved drug delivery and efficacy in reducing tumor size in mice, outperforming traditional individual drug treatments
View Article and Find Full Text PDF

The discovery of mutations, particularly the KRASG12C variant, has been a milestone in understanding the molecular underpinnings of non-small cell lung cancer (NSCLC). These mutations are associated with aggressive tumor behavior and resistance to conventional therapies, highlighting the urgent need for targeted interventions. In this comprehensive review, we analyze the advancements in KRAS G12C inhibitors for the treatment of non-small cell lung cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!